Related Experiment Videos
De-escalation therapy in ventilator-associated pneumonia
Jordi Rello1, Loreto Vidaur, Alberto Sandiumenge
1Critical Care Department, Joan XXIII University Hospital, University Rovira i Virgili, Tarragona, Spain.
Critical Care Medicine
|January 11, 2005
Summary
Antibiotic de-escalation is key in managing ventilator-associated pneumonia (VAP). This strategy is more successful in early-onset VAP and less so with specific bacteria, impacting patient outcomes.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Ventilator-associated pneumonia (VAP) is a significant complication in intensive care units.
- Optimizing antibiotic therapy is crucial for improving patient outcomes and reducing resistance.
Purpose of the Study:
- To evaluate the feasibility and impact of de-escalating antibiotic therapy in patients diagnosed with VAP.
- To identify factors influencing the success of antibiotic de-escalation in VAP management.
Main Methods:
- A prospective observational study was conducted over 43 months in a medical-surgical intensive care unit.
- One hundred fifteen patients with VAP received initial broad-spectrum antibiotics, followed by reassessment based on clinical response and microbiology.
- Quantitative cultures from bronchoscopic examination or tracheal aspirates were used to guide therapy modification.
Main Results:
- De-escalation was the most frequent reason for antibiotic therapy modification (31.4% to 38%).
- Inappropriate antibiotic therapy was linked to increased intensive care unit mortality (14.4% excess).
- De-escalation was less frequent in late-onset VAP and in the presence of nonfermenting Gram-negative bacilli.
Conclusions:
- Antibiotic de-escalation is a primary strategy for modifying VAP treatment.
- Early-onset VAP is more amenable to de-escalation than late-onset VAP.
- Quantitative respiratory sampling methods showed comparable impacts on mortality and de-escalation rates.